Drawing for Serial No. 79378834

USPTO serial 79378834

Serial No. 79378834

Reviewed by CopyMark Law Group

Reg. 7602246Status 700Registered
Filing date
Status date
Registration date
Dec 17, 2024
Examiner
STRUCK, ROBERT J
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with Serial No. 79378834?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Nazly Aileen Bayramoglu

Nazly Aileen Bayramoglu Bayramoglu Law Offices LLC1540 West Warm Springs Road Suite 100No. 6 Zhujiang East Road,Henderson, NV 89014

Goods and services

ClassDescriptionStatusFirst use
005medicines for human purposes for the treatment of cancer, hematological tumors, solid tumors, autoimmune diseases, and regulation of the immune system; pharmaceutical preparations for the treatment of cancer, hematological tumors, solid tumors, autoimmune diseases, and regulation of the immune system; drugs for medical purposes, namely, medicines for the treatment of cancer, hematological tumors, solid tumors, autoimmune diseases, and regulation of the immune system; blood for medical purposes; biological preparations for medical purposes for the treatment of cancer, hematological tumors, solid tumors, autoimmune diseases, and regulation of the immune system; stem cells for medical purposes; immunostimulants; injectable medicinal solutions, namely, medicinal preparations for the treatment of cancer, tumors, autoimmune diseases, and regulation of the immune system; biochemical medicines for the treatment of cancer, tumors, autoimmune diseases, and regulation of the immune system; Blood products, namely, blood plasmaACTIVE—
035Import-export agency services; marketing; retail store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies; wholesale store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies; retail and wholesale store services featuring medicines; retail and wholesale store services featuring pharmaceutical preparations; retail and wholesale store services featuring sanitary preparations; retail and wholesale store services featuring medical suppliesACTIVE—
042Technological research in the field of evaluation of efficiency and safety of medication; conducting technical project studies in the field of evaluation of efficiency and safety of medication; scientific laboratory services; scientific research; chemical analysis; chemical research; biochemical research and analysis; medical and scientific research, namely, conducting clinical trials for others; biological researchACTIVE—
044T-cell treatment therapy services; blood bank services; human tissue bank services; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; hospital services; medical clinic services; medical assistance; telemedicine services; nursing, medical; health careACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 21, 2025FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
May 28, 2025FICSFINAL DISPOSITION NOTICE SENT TO IB—
May 28, 2025FIMPFINAL DISPOSITION PROCESSED—
Mar 17, 2025FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 1, 2025OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Feb 12, 2025OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Feb 12, 2025OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Dec 17, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Dec 17, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 29, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 29, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 9, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 20, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 22, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 21, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 21, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 19, 2024RFNTREFUSAL PROCESSED BY IB—
Feb 28, 2024RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Feb 28, 2024RFRRREFUSAL PROCESSED BY MPU—
Feb 7, 2024RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 6, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 30, 2024DOCKASSIGNED TO EXAMINER—
Sep 23, 2023MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 19, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 14, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance